194.62MMarket Cap-3522P/E (TTM)
4.940High4.590Low255.71KVolume4.720Open4.670Pre Close1.21MTurnover0.71%Turnover RatioLossP/E (Static)41.85MShares7.28052wk High3.99P/B167.86MFloat Cap3.89052wk Low--Dividend TTM36.10MShs Float418.400Historical High--Div YieldTTM7.50%Amplitude2.560Historical Low4.729Avg Price1Lot Size
Zevra Therapeutics Stock Forum
Zevra Therapeutics Inc - Reported Positive Topline Results From Kp1077 Phase 2 Trial in Idiopathic Hypersomnia
MT Newswires· 1 min ago
NEWS
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
New long-term real-world data from Zevra's Expanded Access Program for Arimoclomol in treating Niemann-Pick Disease Type C was highlighted at the SIMD 45th Annual Meeting.
The data showed a consistent safety profile and a clinically meaningful slowing of disease progression in adults with NPC.
...
NEWS
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
Zevra Therapeutics, Inc. secures a new $100M credit facility led by Perceptive Advisors and Healthcare Royalty to support its rare disease therapeutics development. The facility includes an initial draw of $60M, with additional tranches available upon meeting certain conditions. Zevra retires existing debt of $43.1M, with net proceeds of $14.0M. The five-...
3 MINUTES AGO, 4:30 PM EDT
VIA GLOBENEWSWIRE
KP1077 demonstrates clinically meaningful benefits for key IH symptoms
Top-line data provide key information for the design of a Phase 3 study
WSJ· 1 min ago
No comment yet